Nirvana Life Sciences Inc. Stock

Equities

NIRV

CA6546521064

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange 12:07:28 2024-04-16 pm EDT 5-day change 1st Jan Change
0.02 CAD -63.64% Intraday chart for Nirvana Life Sciences Inc. 0.00% 0.00%
Sales 2022 - Sales 2023 - Capitalization 1.02M 1.4M
Net income 2022 -5M -6.83M Net income 2023 -1M -1.37M EV / Sales 2022 -
Net cash position 2022 35.77K 48.89K Net Debt 2023 45.9K 62.75K EV / Sales 2023 -
P/E ratio 2022
-3.68 x
P/E ratio 2023
-0.68 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 39.95%
More Fundamentals * Assessed data
Dynamic Chart
Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023 CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Full Year Ended April 30, 2023 CI
Nirvana Life Sciences Inc. completed the acquisition of Medsmart Dispensary Inc. CI
Nirvana Life Sciences Inc. entered into a letter of intent to acquire Medsmart Dispensary Inc. for $0.13 million. CI
Nirvana Life Sciences Inc. announced that it has received funding CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023 CI
Nirvana Life Sciences Inc. Announces Resignation of Chris Hoffmeister from the Board of Directors CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022 CI
Nirvana Life Sciences Agrees to Buy Licensed Distributor of Patented, Herbal Treatment for Opiate Addiction MT
Nirvana Life Sciences Inc. Appoints Sheldon Inwentash to the Company's Board of Directors CI
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2022 CI
Nirvana Life Sciences Inc. Announces Method for Producing MDMA That Reduces Manufacturing Time by Two Thirds CI
Nirvana Life Sciences Inc. Auditor Raises 'Going Concern' Doubt CI
More news
1 day-63.64%
Current month-66.67%
1 month-55.56%
6 months-50.00%
More quotes
1 month
0.02
Extreme 0.02
0.06
Current year
0.01
Extreme 0.01
0.06
1 year
0.01
Extreme 0.01
0.12
3 years
0.01
Extreme 0.01
0.95
5 years
0.01
Extreme 0.01
0.95
10 years
0.01
Extreme 0.01
0.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 17-12-03
Director of Finance/CFO - 17-04-09
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 68 22-11-08
Director of Finance/CFO - 17-04-09
Director/Board Member 30 20-12-31
More insiders
Date Price Change Volume
24-04-26 - -100.00% 860

Delayed Quote Canadian Securities Exchange, April 16, 2024 at 12:07 pm EDT

More quotes
Nirvana Life Sciences Inc. is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The Company has selected two products for its first phase of development: a one-per-day slow release gel cap that assists transition from opioids to non-addictive pain relief therapies, and a one-per-day slow release gel cap that delivers non-addictive pain relief. Any number of therapeutic medicines and products are created from its formulations. The Company is also engaged in growing several genera and species of fungi (including rare and hybrid varieties) with a batch consistency.
More about the company